RENB (Renovaro) Momentum Rank : 2 (As of Apr. 17, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Renovaro Momentum Rank?

Renovaro has the Momentum Rank of 2.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Renovaro's Momentum Rank

For the Biotechnology subindustry, Renovaro's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renovaro's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovaro's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Renovaro's Momentum Rank falls into.

Save Embed

;

Save Embed

;

Renovaro Momentum Rank Related Terms

Thank you for viewing the detailed overview of Renovaro's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovaro Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

2Q5:Germany

Address

2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067

Website

https://www.renovarogroup.com

Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.

Executives

Anderson Wittekind William	10 percent owner	8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leni Boeren	director	2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks	director	CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard	10 percent owner	VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette	officer: Executive Vice President	2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu	10 percent owner	2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev	director, 10 percent owner	FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler	other: Former director see note below	330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol	director	606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen	director	STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche	officer: Chief Financial Officer	318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne	director	NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Leire, Eric Jean Marie	director, officer: CEO; President	C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060